{"disease":{"id":"staphylococcal-infection","name":"staphylococcal infection"},"drugs":{"marketed":[{"drug_id":"dalbavancin","indication_name":"Staphylococcal infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dalvance","generic_name":"DALBAVANCIN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"","drug_class":"Lipoglycopeptide Antibacterial","quality_score":65,"revenue":"260.0","mechanism":"Dalvance works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death."},{"drug_id":"fusidic-acid","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Synergy for Staphylococcal Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"gentamicin","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Synergy for Staphylococcal Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"tobramycin","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"oritavancin","indication_name":"Staphylococcal infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orbactiv","generic_name":"ORITAVANCIN","company_name":"Melinta Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Lipoglycopeptide Antibacterial","quality_score":65,"revenue":null,"mechanism":"Orbactiv works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death."},{"drug_id":"xydalba","indication_name":"Staphylococcal infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xydalba","company_name":"Correvio International Sarl","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Synergy for Staphylococcal Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl3989564","indication_name":"Serious Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"orbactiv","indication_name":"Staphylococcal infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Orbactiv","company_name":"Melinta Therapeutics, LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03456544","title":"Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06479837","title":"Modeling Host-Pathogen Interaction Using Lymphoid Organoids","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT07155590","title":"Subphenotype- and Complication-guided Adjunctive Fosfomycin Therapy for Staphylococcus Aureus Bacteraemia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":369,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT04141787","title":"Ceftriaxone as Home IV for Staph Infections","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":310,"lead_sponsor_name":"Vancouver Island Health Authority","has_results":false},{"nct_id":"NCT01419184","title":"Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02814916","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06805994","title":"Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT01827358","title":"Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT07524894","title":"Staph Nasal Decolonization to Improve Function and Feeding: A Randomized Clinical Trial (SNIFF).","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"David Palma","has_results":false},{"nct_id":"NCT03915470","title":"Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Destiny Pharma Plc","has_results":true},{"nct_id":"NCT02502474","title":"Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne","phase":"NA","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT05899140","title":"Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Frieder Schaumburg","has_results":false},{"nct_id":"NCT02694458","title":"Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02595112","title":"Study of Staphylococcus Aureus Colonization of the Posterior Nasal Cavity in Patients Undergoing Otorhinolaryngologic Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT04409392","title":"Staphylococcus Lugdunensis Prosthetic Joint Infection","phase":"","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07013864","title":"Staphylococcus Haemolyticus in the Neonatal Intensive Care Unit of CHSD in 2023: Analysis and Trends","phase":"","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Centre Hospitalier de Saint-Denis","has_results":false},{"nct_id":"NCT00911430","title":"Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection","phase":"","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02782078","title":"Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}